The approval of ursodeoxycholic acid (UDCA) for primary biliary cholangitis (PBC) in 1997 marked a pivotal turning point in ...

Shares of Mirum Pharmaceuticals, Inc. MIRM have rallied 90.9% in the past six months compared with the industry’s increase of ...

As the largest internal organ in the human body, the liver supports a wide range of responsibilities related to metabolism, ...

The conditional marketing approval for Ocaliva (obeticholic acid) has been revoked with immediate effect, following a standoff between the EMA and Advanz Pharma Ltd., the company that markets the ...

Cour Pharmaceuticals plans to move its HQ out of Skokie for a custom-built, 50,000 square-foot space in Evanston Labs.

Genfit licensed Iqirvo's global rights to Ipsen in 2021, securing milestone payments and royalties. Read why GNFT stock's ...

Topline results were announced from a phase 3 trial evaluating linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).

The London-based pharmaceutical company said that in cholestatic pruritus, also known as relentless itch, in primary biliary cholangitis, an autoimmune disease known as PBC, linerixibat showed a ...

Individuals with primary biliary cholangitis and diabetes may experience worse outcomes, such as progression to end-stage ...

The study enrolled 238 people with primary biliary cholangitis (PBC) and cholestatic pruritus, a medical term for relentless ...

Bexotegrast, an oral inhibitor of αvβ6 and αvβ1 integrins, was shown to improve markers and symptoms of cholestasis and stabilized markers of liver fibrosis in participants with primary sclerosing ...